Risks from rapid technological innovation, competition and intellectual property rights
First written in FY2019. 3 of 4 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2026: 4 of 28 companies on the "Worse" side.
66 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「The pharmaceutical industry is intensely competitive, with numerous companies and research institutions in Japan and overseas, including global industry leaders, and technological innovation is advancing rapidly.」
The risk of being unable to maintain an advantage over competitors amid rapid technological innovation and an intense competitive environment has been reaffirmed. - FY2024RestatedAnnual report
「The Company is confident that its regenerative-inducing pharmaceuticals® currently represent highly novel regenerative medicine technology and are academically superior to other regenerative cell therapies and similar products in terms of safety, efficacy and applicability. However, there is always a risk of being overtaken by rapid technological innovation or of unexpected side effects emerging, which could have a material impact on the Company’s business strategy and financial results.」
The Company has reaffirmed its awareness of the risks associated with rapid technological innovation, competition, unexpected side effects and the need to address intellectual property issues. - FY2022RestatedAnnual report
「The Company needs to stay ahead of potential competitors and develop products that surpass other companies’ intellectual property.」
The need to stay ahead of competitors and address intellectual property issues amid rapid technological innovation and an intense competitive environment has been reaffirmed. - FY2019First statedAnnual report
「Under these management conditions, the Company faces 5 main immediate issues that it must address, as set out in ①–⑤ below.」
The Company explains that it needs to stay ahead of potential competitors in the regenerative medicine field and develop products that surpass other companies’ intellectual property. It has also disclosed the possibility of intellectual property disputes with third parties and technological obsolescence.